Petar Vazharov, Alvogen’s executive vice president for Asia Pacific, and, Jefferson Wang, general manager of Lotus, provide insights into Lotus’ tremendous evolution from a local generics company into a regional player holding international ambitions, and highlight the main achievements of this fast-growing company since it joined the Alvogen group in 2014.
In 2014, Alvogen became the first foreign company to acquire a majority stake in a Taiwanese pharmaceutical company, while Lotus used the proceeds of the share issue to acquire several of Alvogen's businesses in Asia. Could you briefly explain what was the strategic thinking that motivated this merger?
"The main challenge in Asia is to find companies that are qualified for regulated markets such as US, Japan and EU, whether it relates to the development and manufacturing of groundbreaking products."
